ARTH has FDA and EMA approval for its bedsore treatment, AC5. Should it be worth more than a MC of 21M?
In a profit-driven healthcare system, those who suffer from bedsores might be SOL.
In the usa, Medicare doesn't cover Pressure Ulcers.
Each year 2.5M patients suffer from bedsores and 60K of them die as a result.
Doctors don't debride necrotic tissue as needs be, because they are afraid that inadequate aftercare will allow the patient to bleed out. This is especially true wherever patients are on blood thinners AND profit motivated curry munching filth run the facility. There is investigative journalism that you won't see in the MSM that shows that white elderly patients are especially SOL when the facility is run by those from subcontintental asia, who like to hire low wage animalistic negroes. Always remember a little bit racism will save your ass.
Black Olives Matter.
AC5 is a self assembling peptide that works whether the patient is on blood thinners or not.
Unfortunately, hiring a sales force would be a sure way for ARTH to go BK. So, its trying to use opinion leaders in social media to get the word out that AC5 can save lives.
ARTH burn is $1M-1.5M/Q. It raises cash to keep the dream alive. Maybe one day BAX or JNJ will acquire it and add their mighty wound-care marketing power to the problem.
There is a rumor that BSX is interested.
I would not invest or even trade.
News 
Market Data 
Discover 
